← All trials
NCT05816226
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2023
- Primary completion
- Apr 30, 2025
- Completion date
- Apr 30, 2025
- First posted
- Apr 18, 2023
- Last posted
- Oct 13, 2023
- Enrollment
- 90
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of the PacificLead sponsor
- University of the PacificReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.